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Nuclear proto-oncogene products transactivate the human papiliomavirus
type 16 promoter
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and D Schadendorf'
'Universitdtsklinikwn Rudolf Virchow, Hautklinik, Freie Universitdt; 2Max Planck Institutfu-r Molekulare Genetik, Abteilung
Schuster, Berlin, Germanuy.
Smarq Human papillomavirus (HPV) type 16 and 18 viral genomes are frequently detected in cervical and
penile cancer biopsies. Although this strongly suggests a prominent role for HPV infection in the development
of genital cancer, other genetic or environmental factors are also involved. Genital cancer is postulated to
result from loss of cellular control functions, which leads to an unregulated expression of HPV oncogenic
proteins. In our study, we determined the trans-activating properties ofnuclear proto-oncogene proteins c-Fos,
c-Jun and c-Myc on P97 enhancer/promoter activity of HPV16. Using a CAT-reporter construct containing
the HPV16 enhancer/promoter element, we investigated the trans-activating effects ofc-Fos, c-Jun, c-Myc, and
E2 in cervical HT-3 cells. c-Fos and c-Jun overexpression resulted in a 3.3- and 3.1-fold up-regulation of CAT
activity. Only 2-fold induction was determined by co-transfection with c-myc and the viral transcription factor
E2. Based on these findings, we investigated the expression of HPV DNA (16 and 18) as well as nuclear
proto-oncogenes (c-fos, c-jun and c-myc) in nine cervical cancers by in situ hybridisation. In six out of nine
carcinomas, HPV16 and/or HPV18 DNA was detectable. All tumours showed an intense and homogeneous
expression ofc-fos and c-jun mRNA, while the signal for c-myc was detectable only in four specimens. These
data suggest that deregulation of nuclear proto-oncogene expression may contribute to an overexpression of
HPV-derived oncogenic proteins (E6 and E7), which is generally hypothesised to be an important step in the
malignant transformation of HPV-associated tumours.
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Certain types of human papillomaviruses have been found to
be highly associated with carcinomas of the human uterine
cervix. The oncogenic human papillomaviruses, particularly
HPV16 and HPV18, have been suggested to play an impor-
tant role in carcinogenesis of this type of neoplasia (zur
Hausen and Schneider, 1987). HPV infections alone are most
likely insufficient for malignant transformation since infection
with high-risk HPV types is quite common (Young et al.,
1989), and only a small proportion of patients eventually
develop cervical cancer after long periods of latency (zur
Hausen, 1986). These observations suggest that additional
factors are required in the multistep process of tumori-
genesis.
In recent years, there has been ongoing controversy about
the role of (proto-)oncogenes in the pathogenesis of cervical
neoplasms. Elevated levels, amplification and/or rearrange-
ment of the c-myc oncogene have been reported in carcin-
omas of the uterine cervix (Ocadiz et al., 1987; Riou et al.,
1987; Bourhis et al., 1990; Cromme et al., 1993), but these
findings have not been confirmed by others (Hendy-Ibbs et
al., 1985; Choo et al., 1989; Hughes et al., 1989). In vitro
studies have, however, clearly shown that those HPV types
which are most commonly found in carcinomas are able to
cooperate with activated oncogenes (ras, myc and fos) to
produce cells with tumorigenic characteristics (Matlashewski
et al., 1987; Storey et al., 1988; Bedell et al., 1989; Crook et
al., 1989). In addition, in some cervical carcinomas and
cervical carcinoma-derived cell lines, integration of papillo-
mavirus sequences has been found near cellular oncogenes,
suggesting that at least in some genital tumours cis-activation
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of cellular oncogenes by HPV may be involved in malignant
transformation (Diirst et al., 1987).
Nuclear proto-oncogenes are localised predominantly in
the cell nucleus and are thought to be implicated in signal
transduction from the cell membrane to the nucleus. Physio-
logically, members of this group of proteins (c-Fos, c-Jun
and c-Myc) are involved in regulatory functions involving
either DNA replication or control of gene expression. It has
been demonstrated that c-fos and c-jun genes encode nuclear
phosphoproteins which are able to complex with each other.
The Jun-Fos heterodimeric proteins, called AP-1, recognise
specific DNA sequences and mediate transcriptional regula-
tory activity which has been demonstrated for several genes
(for review see Distel and Spiegelman, 1990; Vogt and Bos,
1990; Angel and Karin, 1991). Papillomaviruses with mucosal
tropism including HPV16 contain up to three binding sites
for AP-1 in their upstream regulatory region (Chong et al.,
1990), which have been revealed to be functionally active
(Cripe et al., 1990).
The role of c-myc in HPV-associated oncogenesis is cur-
rently under discussion. Recently, it has been demonstrated
that c-Myc binds DNA specifically (Blackwell et al., 1990;
Prendergast and Zif, 1991). However, the set of genes regu-
lated by this nuclear proto-oncogene is unknown, indicating
that the direct biochemical actions of the c-Myc protein
remain unclear.
Since nuclear proto-oncogenes with potential gene-regula-
ting activity might be involved in human papillomavirus-
associated carcinogenesis, we have investigated the trans-
activating properties of c-Fos, c-Jun and c-Myc on the P97
promoter, which controls the expression of E6 and E7 onco-
proteins in HPV16. Using in situ hybridisation, we compared
these in vitro results with proto-oncogene expression patterns
m cervical carcinomas.
Materials and mnetbod
Cell culture
HT-3 cells (kindly provided by P.G. Fuchs, Erlangen, Ger-
many) derived from a cervical carcinoma (Fogh and Trempe,1975) were cultured in RPMI-1640 medium (Gibco Labora-
tories) containing 10% fetal calf serum (FCS), supplemented
with penicillin (l00Uml') and streptomycin (l00jigmlI').
HT-3 cells are free of endogenous papillomavirus genomes
(Yee et al., 1985).
Construction ofplasmids
The HPV-16 DNA cloned into pBR322 has been described
(Durst et al., 1983) and was kindly provided by H zur
Hausen of the Deutsches Krebsforschungszentrum, Heidel-
berg, Germany. A DNA fragment corresponding to the long
control region (LCR) of HPV16 (5'EcoRI, 3'Sau96I, nucleo-
tides 7453-112) was cleaved from the HPV16 genome and
cloned by blunt end ligation into the pCAT-basic plasmid
(Promega, Heidelberg, Germany) at the XbaI site, generating
the pHPV16LCR (Figure 1). Insert-containing clones were
identified using restriction analysis.
CAT-reporter plasmids pCMV-CAT, pRSV-CAT and
pSVE-CAT containing virus enhancer/promoter sequences
are described elsewhere (Artuc et al., 1993). Several expres-
sion plasmids for proto-oncogenes and HPV16-derived E2
were used in this study and have been described previously:
HPV16-denrved E2 expression vector p859 and precursor
plasmid p77.01 (Phelps and Howley, 1987), pSVfos (Sch6n-
thal et al., 1988) and pSV2-myc-2 (Kingston et al., 1984).
The c-jun expression vector (p131-1) was constructed in-
troducing the c-jun gene derived from RSVc-Jun (Angel et
al.. 1988) in a pECE expression plasmid (Pharmacia, Frei-
burg, Germany). The eukaryotic expression plasmid (pECE)
was used as a control (Ellis et al., 1986).
For in situ hybnrdisation (ISH), specific probes were
generated using a U937 cDNA library. According to stan-
dard procedures, polymerase chain reactions were performed
to generate specific DNA fragments (Schadendorf et al.,
1991). For amplification, primers for c-fos (5'-GCCGTCTC-
CAGTGCCAACI-ICATlTCCC-3'; 5'-CTTCACACCGCCA-
GCCCTGGAGTAAGC-3') generated a 180 bp DNA frag-
ment, for c-mrnc (5'-AATGTCAAGAGGCGAACACACAA-
CGTC-3': 5'-TITAAGGATAACTACCITrGGGGGCCTIT-3')
a 135 bp fragment and for c-jun (5'-CTCACCTCGCCCGA-
CGTGGGGCTGCTC-3'; 5'-TTCGGCCAGGGCGCGCAC-
GAAGCCCTC-3') a 180 bp fragment. The identity of the
fragments was verified by cloning in a pUCl9 vector via the
SinaI site and dideoxy sequencing. The cellular proto-onco-
gene DNA (c-onc) fragments were cloned in the HinallI-and
EcoRI-digested pSP72 (Promega, Heidelberg, Germany) or
pAM18 vectors (Amersham Buchler, Braunschweig, Ger-
many) via sticky end ligation using the EcoRI/HindIII sites.
Plasmids were linearised with EcoRI before transcription
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with T7 RNA polymerase was performed (DIG-RNA labell-
ing kit; Boehringer Mannheim, Germany).
DNA transfection
DNA transfection was performed as described previously
(Felgner and Ringold, 1989). Bnrefly, HT-3 cells were seeded
into 100 mm plates at a density of 12 000 cells cm2. Cultures
were transfected 1 day after they had reached 50-60%
confluency. Transfection was performed with Lipofectin
(Gibco-BRL, Eggenstein, Germany), with a total of 5 tg of
DNA per 100 mm dish (2jg of CAT plasmid, 1 gg of f-Gal
plasmid and 2 ig of expression vector or pUC19) for 15 h.
After transfection, cells were incubated for 48 h at 37C in
5% carbon dioxide atmosphere in 5 ml of RPMI supp-
lemented with 10% FCS. Thereafter, cells were washed with
phosphate-buffered saline (PBS) and collected. HT-3 cells
were resuspended in 150.l of 0.125 M Tris buffer at pH 7.8
and lysed by freezing and thawing. Supernatants were stored
at -20°C. The protein concentration of the lysates was
determined according to Lowry et al. (1951). After heating
the extract at 65°C, the CAT assay was performed.
CAT assay
CAT assays were performed as described previously (Gor-
man et al., 1982). Bnrefly, cell extracts were incubated with
['4CJchloramphenicol (40-50 mCi mmol-'; NEN, Boston,
MA, USA) and 4 mM acetyl coenzyme A (Pharmacia) in
40 mM Tris-HC, pH 7.8, at 37°C for up to 2 h. Acetylated
chloramphenicol derivatives were extracted with ethylacetate
and separated by ascending thin-layer chromatography.
Thin-layer plates (Schleicher & Schuell, Dassel, Germany)
were exposed to the X-ray film for 48 h to localise the
acetylated products. Thereafter, the radioactive spots were
scraped from the plates for quantification by liquid scintilla-
tion. Some trans-activation experiments were performed with
an alternative standard protocol (Sambrook et al., 1989).
After incubation of the cell extracts in the CAT assay buffer
containing ['4Clacetyl coenzyme A (40 mCi mmol 1; NEN,
Bad Homburg, Germany), 90gg ml-' chloramphenicol and
2.5 mM Tris-HCI pH 7.8, quantification was performed in a
liquid scintillation fluid using Insta-Fluor (Packard, USA).
As determined by independent experiments, both protocols
gave the same results (data not shown).
To determine transfection efficiency, f-galactosidase (P-
Gal) tests were performed. The assay buffer for f-galac-
tosidase contains 100 nM Hepes, 150mM sodium chloride,
4.5 mM magnesium hemi-aspartate, 1% bovine serum
albumin (BSA), 0.05% Tween 20 pH 7.25 and 3.3 mM
chlorophenol-red-f-Io-galactopyranoside (Boehringer Mann-
heim, Germany). Lysates were diluted 1:25 in substrate
buffer and incubated for 60-120 min at 37C. P-
Galactosidase activities were determined spectrophotomet-
rically at 570 nm and compared with a standard (-
galactosidase: Promega, Madison, WI, USA).
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Fiwe I Construction of the pHPV16LCR plasmid. The regula-
tory segment of the HPV16-LCR was inserted into the XbaI site
of a CAT plasmid. Binding sites for AP-1 and E2 are indicated.
The underlining dashed bar indicates the fragment with strong
enhancer activities (Chong el al., 1990).
In situ hybridisation
Paraffin-embedded, formalin-fixed sections of primary cer-
vical carcinoma specimens (n =9) were investigated using
DNA and RNA in situ hybridisation. All tumours were
classified as invasive epidermoid (squamous cell) carcinomas
of the cervix. HPV16/18 detection was carried out using the
commercially available in situ Ultradig kit (Boehringer),
according to the manufacturer's instructions. In order to
investigate the c-onc expression in HT-3 cells, the unstim-
ulated cells were incubated in 5% formalin for 20 min. After
resuspension in 1% agarose, the cells were paraffin embed-
ded.
For riboprobe in situ hybridisation, sections were dewaxed
twice in xylol for 20min. After hydration, the slides were
incubated in 0.2 N hydrochloric acid for 20 min. Sections
were treated with pronase (0.75 mgml'- PBS, pH 7.2, for
Omin), followed by fixation in 4% paraformaldehyde forPbm uW H16
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20 min. Thereafter, slides were incubated in 0.25% acetic
anhydride in a 0.1M triethanolamine (pH 8.0) for 10miO ,
followed by ethanol dehydration. Prehybridisation was per-
formed using 300 lA of prehybridisation solution [50% for-
mamide; 0.3% sodium chloride, 10 mM Tris-HCI pH 7.5,
10 mm sodium phosphate, pH 6.8, 1 x Denhardt's, 250#g
ml'1yeast t-RNA, 5 mM EDTA, 10 mM dithiothreitol
(DMT), 10% dextran sulphate]. Slides were placed in a
humidified chamber at 52°C. Three hours later, 100gul of the
antisense or sense solution containing 50 ng of labelled RNA
was added to the prehybridisation solution on each section.
After 16 h, slides were washed for 4 h in a formamide solu-
tion (50% formamide/10 mM DTT/0.5 M sodium chloride,
0.1M Tris-HCI pH 7.5, 0.1M sodium phosphate, 0.05M
EDTA pH 8.0, 10 x Denhardt's) at 52C, followed by two
washes with TES (1OmM Tns-HCI pH 7.5, 1 mM EDTA
pH 8.0, 0.5 M sodium chloride). After digestion with RNAse
A (20mgml-') in TES for 10min at 3rC, sections were
washed in TES again at 37C. Finally, stringent washing
steps were performed using 2 x SSC and 0.1 x SSC at room
temperature.
Immunohistochemistry was performed according to the
protocol of Boehringer Mannheim. Briefly, slides were wash-
ed in buffer 1 (100 mM maleic acid, 100 mM sodium chlonrde,
0.3% Triton X pH 7.5) for 2 min. Sections were preincubated
in 1% Blocking Reagent (Boehringer Mannheim, Germany)
containing 10% normal sheep serum for 1 h at room
temperature. Thereafter, 200 gi of the anti-digoxigenin con-
jugate (1:500 in buffer 1 containing 10% normal sheep
serum) was placed on the slides for 3 h at room temperature.
Washing steps were repeated, 5 min in buffer 1 and 5 min in
a buffer containing 100 mM Tris-HCl, 100 mM sodium
chloride, 50 mM magnesium chloride (pH 9.5), followed by
incubation of the sections in colour solution (per ml: 4.5 gl of
4-nitroblue tetrazolium, 4.5 glI of 5-bromo-4-chloro-3-indolyl-
phosphate and 3.8 mg of levamisole) at room temperature in
the dark. Sixteen hours later, the reaction was stopped by
washing the slides in 10 mM Tris-HCl, 1 mM EDTA pH 8.0
for 5 min. Finally, the sections were mounted in Kaiser's
glycerin-gelatin without counterstain.
To estimate the amount of specific mRNA. expression in
the cells and tissues, the signal intensity of the colour was
compared after 16 h of immunological detection (-, no sig-
nal; +, weak signal; + +, moderate signal; + + +, strong
signal).
Results
Activities ofvarious eukaryotic promoters in HT-3 cells
Sufficient expression of trans-activating proteins as well as a
sufficient promoter activity of the reporter gene are pre-
requisites for trans-activation experiments. Furthermore,
since it has been shown that eukaryotic promoter activities
show cell type-dependent activity (Artuc et al., 1993), we
determined the activities of various promoters including the
human papillomavirus type 16, the cytomegalovirus (CMV),
simian virus (SV40) and Rous sarcoma virus (RSV) pro-
moters in HT-3 cells. As shown in Figure 2, all plasmids
containing promoter and enhancer sequences were active in
HT-3 cells. The CMV promoter displayed the strongest CAT
activity (98.5%), followed by RSV (24.1%) and SV40 early
promoter (14.2%). The HPV16 (pHPV16LCR) promoter had
a basal activity (4.6%) which was one-fifth of that of the
RSV promoter. The promoterless plasmid and the SV40
promoter plasmid without enhancer region showed identical
low background CAT activities (Table I).
Trans-activation ofnuclear proto-oncogenes and E2
In order to investigate the trans-activating properties of
nuclear proto-oncogenes on the HPV16 P97 enhancer/
promoter, we co-transfected the HPV16 reporter plasmid
with plasmids expressing the c-Fos, c-Jun, c-Myc and
HPV16-E2 proteins in HT-3 cells (Figure 3, Table II). CAT
activity was stimulated 3.1- and 3.3-fold by c-Jun and c-Fos
respectively. A weak but reproducible stimulation was detec-
table by co-transfecting the c-myc (1.9-fold) and E2 plasmids
(2.1-fold). As shown in Figure 3, co-transfection of the con-
trol plasmids pECE or p77.01 gave only minor background
activity. These data indicate that overexpression of nuclear
proto-oncogenes in HT-3 cells resulted in a clear induction of
the HPV16 P97 promoter activity.
Table I Promoter activates in HT-3 cells. pHPV16LCR,
pCMV-CAT, pRSV-CAT, pSVE-CAT, pCAT-promoter and
pCAT-basic plasmids were transfected in HT-3 cells
Plasmid Relative CAT activity
pCAT-promoter 2.0
pCAT-basic 2.1
pSVE-CAT 14.2
pRSV-CAT 24.1
pCMV-CAT 98.5
pHPV16LCR 4.6
Relative CAT activities are expressed as a percentage of
acetylation of the suppklmented chloramphenicol.
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Fugwe 2 Promoter activities in HT-3 cells. Transient transfec-
tion experiments in HT-3 cells were carried out with pCAT-
promoter, pCAT-basic, pSVE-CAT, pRSV-CAT, pCMV-CAT
and pHPV16-LCR plasmids. The thin-layer chromatograph
shows the results of a representative CAT assay.
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Fugwe 3 Transcriptional activation of the human papillomavirus
promoter/enhancer P97 (pHPV16LCR) by c-myc (pSV2-myc-2),
c-jun (pl3l-l), c-fos (pSVfos) and HPV16-derived E2 (p859).
Transient co-transfection experiments were performed in HT-3
cells. A thin-layer chromatograph of a representative CAT assay
is shown. Controls: pECE represents the empty control expres-
sion vector used for the oncogenes and p7701 the empty expres-
sion vector for expression of HPV-E2 (p859).
1020Table H Activation of the human papillomavirus pro-
moter/enhancer P97 (pHPV16LCR) by c-fos, c-jum, c-myc and
HPV16-derived E2 (p859) in HT-3 cells
Number of Relative CAT activity
Plamid experiments (±s.d.)
p77.01 3 1
p849 (E2) 3 2.1 0.3
c-fos 6 3.3±0.5
c-jun 6 3.1 0.5
pECE 6 1
c-mvc 6 1.9± 0.5
Induction of CAT activity was calculated relative to the basal level
obtained with pECE. The transactivating functions of E2 (p859)
were quantified relative to the activity of p77.01.
Table m Analaysis of H1PV16/18 DNA and c-onc expression in
HT-3 cells and nine invasive cervical carcinomas by in situ
hybridization
Specimens c-fos c-jun c-myc HPV16/18
HT-3 cells + + +
No. 1 +++ +++ - ++
No. 2 ++ ++ + ++
No. 3 ++ + - -
No. 4 ++ ++ + ++
No. S +++ ++ - ++
No. 6 + + + -
No. 7 + + + ++
No. 8 + + + + - ++
No. 9 + ++ -
The expression of the riboprobe in situ signal was semiquantified
by comparing the signal intensity of the colour after 16 h of
immunological detection (-, no colour, +, weak signal; + +,
moderate signal; + + +, strong signal).
Proto-oncogene expression in HT-3 cells and HPV-positive
cervical carcinomas
In order to study the c-onc and HPV expression in cervical
carcinomas, we performed in situ hybridisation in HT-3 cells
and nine invasive epidermoid (squamous cell) carcinomas of
the cervix. The HPV-negative HT-3 cells showed no or only
weak expression of c-myc and c-fos mRNA, while the c-jun
sigal appeared moderate (Table HII). Six of nine cervical
tissues showed HPV16/18 DNA. In contrast to the normal-
appearing cervical mucosa or stroma (Figure 4), c-fos and
c-jun mRNA were expressed in most tumours at high levels.
Comparing the signal intensity ofc-fos and c-jun, both proto-
oncogenes were expressed in most neoplasms at similar levels.
Differences in patterns of proto-oncogene expression between
HPV16/18-positive and HPV16/18-negative cervical carcino-
mas were not detectable. Four of nine tumour specimens
expressed detectable amounts of c-myc mRNA at low
levels.
Disusssio
In recent years, great interest has been focused on transcrip-
tional regulation of human papillomaviruses since this might
help to understand the factors involved in the multistep
process of carcinogenesis (Cripe et al., 1990; Chong et al.,
1990, 1991). In the present study, we have investigated the
transcriptional regulation of different nuclear proto-onco-
genes on the P97 enhancer/promoter using the cervical car-
cinoma cell line HT-3. This cervical carcinoma cell line is free
of endogenous papillomavirus gene products and shows only
a moderate expression of c-onc (Table III), making it a good
model to study the trans-activating properties of HPV and
nuclear proto-oncogenes in its natural host cells. After trans-
fection in HT-3 cells, all viral promoters used in our study
were transcriptionally active. In agreement with other studies
(Chong et al., 1991), the strongest activity was detectable for
the CMV enhancer/promoter, which is considered to be ubi-
Priloncogsandsu HPV16
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quitously active (Boshart et al., 1985). The activity of the
HPV16 enhancer/promoter was about one-third that of the
pSVE-CAT (4.6% vs 14.2%), indicating that the P97 enhan-
cer/promoter is about 5- to 30-fold more active in cervical
HT-3 cells than in primary human keratinocytes (Romanczuk
et al., 1990). After co-transfection with c-fos or c-jun expres-
sion plasmids, the transcriptional activity in HT-3 cells was
stimulated about 3.3- or 3.1-fold respectively. This is in
agreement with data described by Cripe et al. (1990), who
found a 7.9-fold increased transcriptional activation after
co-transfection of a P97 reporter plasmid with c-jun. In con-
trast to our study, transfection experiments were performed
in undifferentiated mouse F9 teratocarcinoma cells, and the
investigators used the P97 reporter plasmid, which contains
an LCR core sequence of only 88 nt. It has been reported
that shortening of enhancer/promoter regions in reporter
plasmids may result in a stronger trans-activation (Zobel et
al., 1992; Ku et al., 1993), which could be the reason for the
stronger trans-activation observed by Cripe et al. (1990).
Infection of keratinocytes with consecutive integration of the
HPV genome is normally not associated with fragmentation
of the HPV enhancer/promoter region. Therefore, we investi-
gated the trans-activating properties with the HPV16 regu-
lative sequence without truncation in accordance with the
situation in vivo.
c-Fos and c-Jun are the major components of the tran-
scription factor AP-1 (Angel and Karin, 1991). It has been
reported that, in contrast to c-Fos, c-Jun proteins are able to
form homodimers with DNA-binding properties (for review
see Distel and Spiegelman, 1990; Angel and Karin, 1991).
However, c-Fos-c-Jun heterodimers have a higher DNA-
binding activity than the c-Jun homodimers. In HT-3 cells,
the endogenous c-jun mRNA level exceeded those of c-fos
(Table HI), suggesting that the induced overexpression of
c-Jun might have led to homodimerisation and a consecutive
trans-activation of the P97 enhancer/promoter.
In agreement with analogous studies which displayed
trans-activating properties of HPVl6-derived E2 on hetero-
logous and homologous reporter plasmids (Cripe et al., 1987;
Phelps and Howley, 1987), we observed a weak trans-acti-
vation of the P97 promoter after p859 co-transfection (Table
II), resulting in a viral E2 protein expression.
In contrast to AP-1 and E2, no potential sequence-specific
DNA binding sites for the c-Myc protein are detectable on
the P97 enhancer/promoter (Figure 1). Since c-Myc showed
activating properties on the HPV16 promoter (1.9-fold), we
suggest that this effect might be explained by indirect
mechanisms which have been demonstrated to be indepen-
dent from trans-activation (Prendergast and Cole, 1989).
To determine the relevance of the observed c-Fos-, c-Jun-
and c-Myc-dependent up-regulation of the HPV16 promoter,
we performed in situ hybridisation studies in nine invasive
cervical carcinomas. In contrast to normal-appearing cervical
mucosa, all tumours showed a strong expression ofc-fos and
c-jun. In agreement with other studies investigating cervical
carcinomas by Northern blot technique and histochemically
(Bourhis et al., 1990; Cromme et al., 1993), expression of
c-myc was detectable only in less than 50% of the carcinomas
investigated.
Recently, c-fos and c-jun expression was investigated in
normal epidermis (Basset-Seguin et al., 1991). It has been
suggested that in those tissues, c-fos and c-jun transcripts are
preferentially located in basal or suprabasal normal kera-
tinocytes and that expression of these proto-oncogenes is
linked to differentiation rather than to proliferation (Basset-
Seguin et al., 1994; Nurnberg et al., 1994). In malignant cells
of squamous cervical epithelium, however, c-fos and c-jun
expression has been found to be distributed in a homogen-
eous pattern throughout the epithelium (Figure 4), indicating
alterations in c-fos and c-jun gene expression.
In conclusion, our data indicate that overexpression of
proto-oncogenes such as c-fos, c-jun and c-myc results in an
activation of the P97 promoter in vitro and might con-
secutively, as observed in vivo, up-mgulate the expression of
oncogenic viral proteins. Therefore, deregulation of proto-P --m- ad HFYl
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Fige 4 Analysis of HPV16/18 DNA and c-fos and c-jun mRNA esson in an invasv cervical carcinoma. The sections were
hybridised with (a) HPV16/18 DNA, (b) c-fos antisense, (c) c-po and (d) control fos sense RNA probes. The control DNA
hybrdisatio and the sense control for c-jun were negative (data not shown). The sctions show an HPV-assocated tumour
infiltrate nea HPV-negtive mucosal epitheium- This tissue speien was negtive for c-myc (no. I in Table I).
Bar = 20 pm.
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oncogene expression might contribute to cervical carcino-
genesis.
Abbreviatio: HPV, human papillomavirus; CAT, chloramphenicol
acetyltransferase; c-onc, cellular proto-oncogenes; GAL, galacto-
sidase; URR, upstream regulatory region; LCR, long control region;
SV40, simian virus; CMV, cytomegalovirus; RSV, Rous sarcoma
virus.
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